A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

Status

Ongoing, recruiting

Phase

Phase I and Phase II (Integrated)- First administration to humans

Sponsor

Sanofi-Aventis Recherche & Developpement

Enrolment target

59

Start

15 Jun 2023

Age 18 Years to any · Sex: All

• —

  Hungary
• —

  Belgium
• —

  Spain
• —

  Czechia
• —

  Italy
• —

  Greece